Windlas Biotech Ltd
Windlas Biotech Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #81 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Company maintains focus on long-term growth across all three verticals: CDMO, Trade Generics & Institutional, and Exports. Windlas Biotech has demonstrated 14 consecutive quarters of consistent revenue growth, reflecting strong execution.
From Windlas Biotech Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Company maintains focus on long-term growth across all three verticals: CDMO, Trade Generics & Institutional, and Exports.
- CDMO vertical showed strong 29% Y-o-Y growth; volume growth expected to be higher than price effects.
- Exports vertical has high potential with ongoing geography and portfolio expansion, plant approvals, and increased business development efforts.
- Trade Generics impacted by discontinuation of codeine products but expected to progressively bridge the gap via new product launches and geographic expansion.
- Capacity utilization with Plant 6 commissioning aims at INR1,100 crore revenue, with potential for 10-15% further increase via operational efficiencies.
2 more points from Windlas Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Windlas Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Plant 6 expansion is targeted to be operational by end of H1 FY2026, with full depreciation impact starting Q2/Q3.
- Plant 6 is an incremental capacity expansion expected to add INR100-150 crores in revenue.
- No immediate new large-scale capex plans currently; focus remains on incremental capacity additions rather than big facility projects.
- Debottlenecking and operational capex will continue to optimize existing plants and improve efficiencies.
- Capacity enhancement projects typically take 6-8 months for machinery installation and qualification.
2 more points from Windlas Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Windlas Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Windlas Biotech Ltd's call on order book
Create a free account to keep reading this call
Windlas Biotech Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹238 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Windlas Biotech's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Windlas Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Windlas Biotech Ltd Q1 FY27 results?
Company maintains focus on long-term growth across all three verticals: CDMO, Trade Generics & Institutional, and Exports. Windlas Biotech has demonstrated 14 consecutive quarters of consistent revenue growth, reflecting strong execution.
What is Windlas Biotech Ltd share price analysis?
Windlas Biotech Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.
Is Windlas Biotech Ltd planning capital expenditure?
Plant 6 expansion is targeted to be operational by end of H1 FY2026, with full depreciation impact starting Q2/Q3.
Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.